Fresenius Medical says fourth-quarter operating profit up 3%
Reuters
Published Feb 19, 2020 18:43
Fresenius Medical says fourth-quarter operating profit up 3%
By Ludwig Burger
FRANKFURT (Reuters) - Germany's Fresenius Medical Care (DE:FMEG) on Wednesday said quarterly adjusted operating income edged 3% higher as growth in dialysis services and products was partly offset by a negative adjustment for accounts receivable in a legal dispute in North America.
Fourth-quarter earnings before interest and tax, adjusted for special items, advanced to 655 million euros ($707 million), the group said in a statement, coming in below a median analyst estimate of 689 million euros, according to a company-provided poll.
The kidney dialysis provider, controlled by diversified healthcare group Fresenius SE (DE:FREG), reaffirmed a guidance for 2020 revenue and net income to grow at a mid- to high single-digit rate in 2020, when measured without currency swings and excluding special items.
The guidance is based on the adjusted results for 2019, including the acquisition of home dialysis company NxStage, it added.
The group added it was too early to quantify the impact of the coronavirus outbreak in China on its Asia-Pacific operations and that its priority was to continue treating its dialysis patients as well as employee safety.
Asia accounted for 11% of its total quarterly revenue of 4.58 billion euros.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.